BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - Results of the German Hodgkin study group

Leukemia and Lymphoma

Volumn 46, Issue 11, 2005, Pages 1561-1567

  Ruffer J U ^a   Ballova, V ^a   Glossmann, J ^a   Sieber, M ^a   Franklin, J ^a   Nogova, L ^a   Diehl, V ^a   Josting, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Early stages; Hodgkin's disease; Radiotherapy; Relapse; Salvage

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GERMANY; HODGKIN DISEASE; HUMAN; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DATABASES, FACTUAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PROCARBAZINE; PROGNOSIS; RADIATION DOSAGE; RADIOTHERAPY; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; VINBLASTINE; VINCRISTINE;

EID: 28244432766     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500178167     Document Type: Article

References (28)

1. Carde P, Noordijk E, Hagenbeek A, Kluin-Nelemans JC, Thomas J, Tirelli U, et al. Superiority of EBVP chemotherapy in combination with involved field irradiation over subtotal nodal irradiation in favorable clinical stage I-II Hodgkin's disease: The EORTC-GPMC H7F randomized trial. Proc Amer Soc Clin Oncol 1997;16:13 (abstr.).
2. Tesch H, Sieber M, Rueffer U, Bnilant C, Reinke T, Hermann R, et al. Second interim analysis of the HD7 trial of the GHSG: 2 cycles ABVD plus extended field radio-therapy is more effective than radiotherapy alone in early stage HD. Blood 1999;94:2113 (abstr.).
3. Roach M 3rd, Brophy N, Cox R, Varghese A, Hoppe RT. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 1990;8:623-629.
4. Specht L, Horwich A, Ashley S. Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin's disease. Int J Radiat Oncol Biol Phys 1994;30:805-811.
5. Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 1997;33:848-853.
6. Healey EA, Tarbell NJ, Kalish LA, Silver B, Rosenthal DS, Marcus K, et al. Prognostic factors for patients with Hodgkin's disease in first relapse. Cancer 1993;71:2613-2620.
7. Hoppe RT. The management of Hodgkin's disease in relapse after primary radiation therapy. Eur J Cancer 1992;28:1920-1922.
8. Cadman E, Bloom AF, Prosnitz L, Farber L, Vera R, Bertino J, et al. The effective use of combined modality therapy for the treatment of patients with Hodgkin's disease who relapsed following radiotherapy. Am J Clin Oncol 1983;6:313-318.
9. Vinciguerra V, Propert KJ, Coleman M, Anderson JR, Stutzman L, Pajak TF, et al. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group. B J Clin Oncol 1986;4: 838-846.
10. Olver IN, Wolf MM, Cruickshank D, Worotniuk V, Ding JC, Cooper IA, Matthews JP. Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease. An analysis of long-term follow-up. Cancer 1988;62:233-239.
11. Santoro A, Viviani S, Villarreal CJ, Bonfante V, Delfino A, Valagussa P, Bonadonna G. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986;70:343-348.
12. Abrahamsen AF, Hannisdal E, Nome O, Elgio RF, Holte H, Hager B, et al. Prognostic variables and results of salvage treatment in Hodgkin's disease. Acta Oncol 1996;35(suppl 8): 67-72.
13. Cooper MR, Pajak TF, Gottlieb AJ, Glicksman AS, Nissen N, Richards F 2nd, et al. The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease. J Clin Oncol 1984;2:748-755.
14. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper HR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1483.
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Ass 1958;53:457-481.
16. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339: 1506-1514.
17. Hartsell WF, Sarin P, Recine DC, Kazlauskas LI, Galinsky DL, Griern KL. Long-term results of curative irradiation in pathologically staged IA and IIA Hodgkin's disease. Radiology 1993;186:565-568.
18. Zijlstra JM, Dressel AJ, Mens JW, Tinteren H, Slotman BJ, Jonkhoff AR, Huijgens PC. Radiation therapy in early stage Hodgkin's disease: long-term results and adverse effects. Hematol J 2002;3:179-184.
19. Zinzani PL, Barbieri E, Gherlinzoni F, Frezza G, Mazza P, Pica A, et al. Radiotherapy in early stage Hodgkin's disease. Leuk Lymphoma 1994;13:285-289.
20. Maurizi Enrici R, Falchetto Osti M, Zurlo A, Anselmo AP, Iacari V, Mandelli F. Long-term results of 60 patients with pathologic stage I & IIA Hodgkin's disease treated with exclusive mantle radiation therapy. Eur J Haematol 1999; 63:126-133.
21. Noordijk EM, Carde P, Mandard AM, Mellink WA, Monconduit M, Eghbali H, et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. Ann Oncol 1994;5(suppl 2): 107-112.
22. Zapatero A, Lopez MA, Cerezo L, De Vidales CM, MarIn A, Perez-Torrubia A. Stage I-III Hodgkin's disease: outcome and pattern of failure following treatment with radiation therapy and chemotherapy in a modern era. Hematology 2002;7: 43-50.
23. Amini RM, Glimelius B, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, Enblad G. A population-based study of the outcome for patients with first relapse of Hodgkin's lymphoma. Eur J Haematol 2002;68:225-232.
24. Wirth A, Chao M, Corry J, Laidlaw C, Yuen K, Ryan G, et al. Mantle irradiation alone for clinical stage I-II Hodgkin's disease: long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 1999;17:230-240.
25. Canellos GP, Young RC, DeVita VD. Combination therapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clin Pharm Ther 1972;13:750-754.
26. Portlock CS, Rosenberg SA, Glatsetin E, Kaplan HS. Impact of salvage treatment on initial relapses in patients with Hodgkin's disease, stages I-II. Blood 1978;51:825-833.
27. DeVita VT Jr, Simon RM, Hubbard SM, Young RC, Berard CW, Moxley JH 3rd, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980;92:587-595.
28. Peschel RE, Hou-Wun Mai D, Dowling S, Knowlton A, Farber L, Fischer JJ. Pathologic stage I and II Hodgkin's disease. Long-term results at three Connecticut hospitals. Conn Med 1991;55:449-452.